GLP-1 manufacturing: why supply is the bottleneck

Here is the counter-intuitive heart of the GLP-1 story: for a long stretch, the problem was not finding customers — it was making enough drug to serve them. Injectable GLP-1s are peptides, large and delicate molecules that are genuinely hard to produce at the scale of tens of millions of patients. That is why GLP-1 manufacturing — unglamorous, capital-hungry, and slow to build — has been the real constraint on the boom, and the quiet picks-and-shovels story behind it.

Where this sits in the ripple

Duopoly · Pill · Factory · Delivery · Access · Consumer ripple · Healthcare ripple · Forces

The factory feeds The Duopoly and the challengers in The Pill. Links up to The Boom. The picks-and-shovels logic mirrors the tools link in our Healthcare series.

What this link is

• Active pharmaceutical ingredient (API) — the drug substance itself, before it is packaged into a dose.
• Fill-finish — the precise, sterile step of putting the drug into vials or pens. A choke-point in its own right.
• CDMO — a contract development and manufacturing organisation: a company that makes drugs (or steps of them) on behalf of others. When demand outstrips a drugmaker's own plants, CDMOs fill the gap.
• Why pills help. Oral small molecules are easier and cheaper to manufacture than injectable peptides — part of why the oral race matters for supply, not just convenience.

The companies

Eli Lilly (LLY) and Novo Nordisk (NVO)

What they do: both makers have committed enormous sums to expanding capacity — Lilly building out API production, and Novo spending roughly $16.5 billion to acquire three large manufacturing sites (from the contract manufacturer Catalent) to secure its own supply. The numbers:. The edge: controlling supply is a moat in this market — the company that can make the drug is the company that can sell it. The risk: capacity built for today's surging demand can become an expensive overhang if the market turns out smaller than the most optimistic forecasts (the central debate in The Forces).

Thermo Fisher Scientific (TMO)

What they do: the supplier and contract manufacturer behind the scenes — Thermo Fisher provides bioprocessing tools, lab supplies, and contract manufacturing across the drug industry. The numbers:. The edge: broad exposure to industry-wide drug production, rather than a bet on any single molecule. The risk: as the big makers in-source their own capacity, demand for third-party manufacturing can soften.

Context, not a profile. Catalent, once a major listed contract manufacturer, was absorbed into Novo's orbit and taken private — a vivid example of how the GLP-1 supply chain consolidated. Switzerland's Lonza is another large CDMO worth knowing, but sits outside the US index.

The bull and bear case

The bull case: supply is the genuine constraint and the genuine moat. Whoever can manufacture at scale captures the demand, and capacity takes years for rivals to replicate.

The bear case: the industry is building capacity against demand forecasts that disagree by tens of billions of dollars. If demand disappoints — or if easier-to-make pills reduce the need for complex injectable capacity — today's shortage could become tomorrow's glut.

What feeds it, what it feeds

The factory turns the makers' molecules into actual doses for The Duopoly and The Pill. Those doses then need hardware to reach patients — next, The Delivery. Back to the map: The Boom.

This article is for information only. It is not medical advice and not investment advice or a recommendation to buy or sell any security. TradeRadarNews is not a licensed financial or medical adviser. Figures are accurate as of June 2026 and will change. Markets carry risk, including loss of capital. Rules, taxes, and available products differ by country — do your own research and consult a locally regulated professional.